Similar articles for PMID: 27127108

Year	Number of Results
1996	1
1998	2
2000	2
2001	1
2002	3
2003	3
2005	3
2006	7
2007	6
2008	7
2009	2
2010	4
2011	10
2012	5
2013	10
2014	4
2015	7
2016	5
2017	5
2018	7
2019	5
2020	12
2021	10
2022	13
2023	5

1

Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response.

Sordillo LA, Sordillo PP, Helson L. Sordillo LA, et al. Anticancer Res. 2016 May;36(5):2085-95. Anticancer Res. 2016. PMID: 27127108 Review.

2

A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.

Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, McDonald KL, Don AS. Abuhusain HJ, et al. J Biol Chem. 2013 Dec 27;288(52):37355-64. doi: 10.1074/jbc.M113.494740. Epub 2013 Nov 21. J Biol Chem. 2013. PMID: 24265321 Free PMC article. Clinical Trial.

3

[Sphingosine kinase 1 and tumor].

Zhang CX, He HW, Shao RG. Zhang CX, et al. Yao Xue Xue Bao. 2013 Jul;48(7):971-8. Yao Xue Xue Bao. 2013. PMID: 24133963 Review. Chinese.

4

Neuroprotective role of sphingolipid rheostat in excitotoxic retinal ganglion cell death.

Nakamura N, Honjo M, Yamagishi R, Kurano M, Yatomi Y, Watanabe S, Aihara M. Nakamura N, et al. Exp Eye Res. 2021 Jul;208:108623. doi: 10.1016/j.exer.2021.108623. Epub 2021 May 19. Exp Eye Res. 2021. PMID: 34022173

5

Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy.

Huwiler A, Pfeilschifter J. Huwiler A, et al. Curr Pharm Des. 2006;12(35):4625-35. doi: 10.2174/138161206779010422. Curr Pharm Des. 2006. PMID: 17168766

6

A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.

Noack J, Choi J, Richter K, Kopp-Schneider A, Régnier-Vigouroux A. Noack J, et al. Cell Death Dis. 2014 Sep 25;5(9):e1425. doi: 10.1038/cddis.2014.384. Cell Death Dis. 2014. PMID: 25255218 Free PMC article.

7

Sphingolipid signaling pathways as potential therapeutic targets in gliomas.

Van Brocklyn JR. Van Brocklyn JR. Mini Rev Med Chem. 2007 Oct;7(10):984-90. doi: 10.2174/138955707782110123. Mini Rev Med Chem. 2007. PMID: 17979800 Review.

8

Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.

Shin KO, Seo CH, Cho HH, Oh S, Hong SP, Yoo HS, Hong JT, Oh KW, Lee YM. Shin KO, et al. Arch Pharm Res. 2014;37(9):1183-92. doi: 10.1007/s12272-014-0340-6. Epub 2014 Apr 1. Arch Pharm Res. 2014. PMID: 24687256

9

Sphingosine kinase, sphingosine-1-phosphate, and apoptosis.

Maceyka M, Payne SG, Milstien S, Spiegel S. Maceyka M, et al. Biochim Biophys Acta. 2002 Dec 30;1585(2-3):193-201. doi: 10.1016/s1388-1981(02)00341-4. Biochim Biophys Acta. 2002. PMID: 12531554 Review.

10

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C. Guillermet-Guibert J, et al. Mol Cancer Ther. 2009 Apr;8(4):809-20. doi: 10.1158/1535-7163.MCT-08-1096. Mol Cancer Ther. 2009. PMID: 19372554

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

134 results

Results by year